Synthorx Appoints Patrick J. Doyle as Chief Business Officer
SAN DIEGO, November 28, 2016 -- /PRNewswire/ -- Synthorx Inc., a biotechnology company using synthetic biology to discover and develop novel protein therapeutics, announced today the appointment of Patrick J. Doyle as chief business officer.
Synthorx Announces $10 Million Series B Financing to Develop and Scale Novel Protein Therapeutics with Improved Pharmacological Properties
SAN DIEGO, July 20, 2016 -- /PRNewswire/ -- Synthorx Inc. announced today the completion of a $10 million Series B financing, led by RA Capital Management and joined by Series...
Synthorx Advances Its Synthetic DNA Technology To Make Its First Full-Length Proteins Incorporating Novel Amino Acids
Synthorx’s synthetic DNA base pair expands the DNA alphabet to enable the creation of more diverse proteins for wide variety of applications in medicine and technology
SAN DIEGO, August 19, 2015...
Synthorx Launches with Breakthrough Synthetic Biology
First example of in vivo replication of a synthetic DNA base pair published in Nature